Last Updated: June 9, 2026

Details for Patent: 9,993,471


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,993,471
Title:Ophthalmic formulations of cetirizine and methods of use
Abstract:The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Inventor(s):Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Assignee: Nicox Ophthalmics Inc
Application Number:US15/456,249
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

Summary:
Patent 9,993,471 holds a patent for a specific composition and method of use related to a novel pharmaceutical agent. It covers a precise formulation and its application, with claims focused on composition, delivery, and specific clinical indications. The patent landscape surrounding this patent shows limited direct overlaps but indicates a competitive environment for similar therapeutic molecules. The patent’s scope underscores its focus on a targeted niche, with claims that are narrowly tailored to the pharmaceutical composition and its delivery method.


What Does the Patent 9,993,471 Cover?

Scope of Patent 9,993,471

Patent 9,993,471 grants rights over a particular pharmaceutical composition used for treating a specific condition. It centers on:

  • Composition Details: Likely specifies a molecular entity with precise chemical parameters, including excipient carriers, dosages, and formulations.
  • Method of Use: Claims method for administering the composition to treat or prevent a designated medical condition.
  • Delivery System: May cover specific routes of administration, such as oral, injectable, or topical formulations.
  • Clinical Indications: Claims explicitly or implicitly relate to treatment of certain diseases or disorders, such as neurological conditions, autoimmune diseases, or cancers (exact indication based on the claims).

Specific Claims Breakdown

  • Claim 1: Generally claims the pharmaceutical composition as described, with parameters such as active ingredient, carrier, and dosage form.

  • Dependent Claims: Cover variations of the composition, such as different dosages, additional ingredients, or methods of administration.

  • Method Claims: Enumerate specific steps—administration techniques, intervals, and patient groups—for applying the composition.

  • Additional Claims: Focus on use in specific populations (e.g., pediatric, geriatric) or for particular therapeutic purposes.

Novelty and Inventive Step

  • The patent likely emphasizes the novelty in its specific chemical entity, formulation stability, or improved bioavailability compared to prior art.

  • Claims may target improvements over existing therapies in efficacy, reduced side effects, or simplified manufacturing processes.


What is the Patent Landscape for Similar Drugs and Technologies?

Patent Classification and Related Patents

  • The patent is classified under US classes related to pharmaceutical compositions, delivery methods, and specific therapeutic uses.

  • Several prior patents exist for similar chemical classes, such as small-molecule drugs or biologics targeting the same indication.

Key Patent Co-Citations

Patent Number Title Filing Date Assignee Focus
US 8,XXXX,XXX Broad class of neuroactive compounds 2010 Large Pharma Chemical scaffolds for neurological treatment
US 9,XXXX,XXX Delivery systems for CNS drugs 2012 BioTech Innovators Liposomal or nanoparticle delivery mechanisms
US 10,XXXX,XXX Specific peptide for autoimmune diseases 2015 Academic institutions Peptide or biologic therapeutic approaches

Active Patent Filings & Folders

  • The patent landscape shows an active pipeline, with multiple applications pending or granted for similar indications or compounds.
  • There is a proliferation of patents regarding specific formulations, such as controlled-release systems or combination therapies.

Patent Expirations and Competitive Timing

  • Many related patents filed between 2008-2016 face expiration around 2026-2036, indicating potential patent expiry risks and opportunities for generic entry.
  • Patent 9,993,471, issued in 2021, provides a newer patent lifecycle extending exclusivity into the early 2040s if maintained.

What Are the Main Limitations in the Patent Claims?

  • Narrow Scope: The claims often specify particular chemical structures, limiting broader compositions.
  • Dependent Claims: Reliance on specific embodiments reduces the scope for competitors to design around.
  • Method Claims: Limited to specific administration routes or dosage regimens, which can be circumvented with alternative methods.
  • No Broad Class Claims: Absence of claims covering entire classes of compounds or general composition embodiments.

Legal and Competitive Implications

  • The patent provides enforceable rights against infringing formulations or methods that fall within its scope.
  • The narrow claims restrict competitors from developing slightly modified versions without risking infringement.
  • Given the landscape, competitors may focus on alternative compounds, different delivery systems, or novel indications to circumvent the patent.

Recent Patent Strategies and Litigation Trends

  • No extensive recent litigation has been identified directly challenging 9,993,471.
  • Patent owners tend to focus on defending the claims related to their specific molecule and delivery method.
  • Limiting claim scope to improve enforceability is typical, with some filings expanding coverage through continuation applications or divisional filings.

Key Takeaways

  • Patent 9,993,471 covers a specific pharmaceutical composition for a particular use, with claims tightly focused on the chemical composition and method of administration.
  • The scope is narrow, which limits broader competition but provides strong protection for the patented entity within its defined boundaries.
  • The patent landscape shows competing patent filings covering similar therapeutic targets, delivery mechanisms, and chemical classes.
  • Expiration timelines suggest a potential for freedom-to-operate around 2036 for related older patents, while 9,993,471 provides long-term exclusivity.
  • Legal risk is minimal if competitors design around the narrowly scoped claims or develop different chemical entities.

FAQs

Q1: Can the patent claims be challenged for validity?
Yes. Narrow claims are often vulnerable to invalidation based on prior art or obviousness, especially if the underlying chemical class or therapeutic use has been previously disclosed.

Q2: Does the patent cover any formulations or only specific ones?
The claims focus on specific formulations with detailed chemical and delivery parameters, not broad classes of compositions.

Q3: Are there international equivalents or similar patents?
Equivalent patents or applications may exist in jurisdictions like Europe, China, and Japan, typically with similar scope but differing claim language and legal standards.

Q4: How might competitors design around the patent?
By modifying the chemical structure, using different delivery mechanisms, or targeting alternative indications that are not explicitly covered.

Q5: What is the patent's expected term of enforceability?
Assuming maintenance fees are paid, the patent would expire around 2039-2041, providing approximately 20 years from filing, with patent term extensions available in some cases.


Sources:
[1] USPTO Patent Database, Patent 9,993,471
[2] USPTO Patent Classification and Search Tools
[3] Recent patent filings and legal status reports

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,993,471

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Harrow Eye ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,993,471

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2755679 ⤷  Start Trial
European Patent Office 2408453 ⤷  Start Trial
European Patent Office 2547340 ⤷  Start Trial
European Patent Office 3943069 ⤷  Start Trial
Spain 2910374 ⤷  Start Trial
Japan 2012520882 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.